Recent investigations have converged on the intersection of GLP|glucose-dependent insulinotropic polypeptide|glucagon receptor activator therapies and DA communication. While GCGR agonists are widely employed for managing type 2 T2DM, their potential effects on reward circuits, specifically governed by dopaminergic pathways, are gaining significant